Efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years old with hereditary angioedema (HAE) in the phase 3, open-label, multicenter SPRING Study

Authors:
  • WLWilliam Lumry
    William Lumry
  • JBJonathan Bernstein
    Jonathan Bernstein
  • RTRaffi Tachdjian
    Raffi Tachdjian
  • HWH. James Wedner
    H. James Wedner
  • WYWilliam Yang
    William Yang
  • MMMarcus Maurer
    Marcus Maurer
  • IMInmaculada Martinez-Saguer
    Inmaculada Martinez-Saguer
  • HFHenriette Farkas
    Henriette Farkas
  • CNChristina Nurse
    Christina Nurse
  • MYMing Yu
    Ming Yu

Abstract
No abstract available